PCA
ADCT icon

Pallas Capital Advisors’s ADC Therapeutics ADCT Stock Holding History

Pallas Capital Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5K Buy
+12,601
New +$36.8K ﹤0.01% 1021

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pallas Capital Advisors's ADCT Position: Q2 2026 in Review

Pallas Capital Advisors opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 12,601 shares worth $13.5K. The stake represents ﹤0.01% of the portfolio and ranks #1021 among its holdings.

114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Pallas Capital Advisors held 12,601 shares of ADC Therapeutics worth $13.5K as of Q2 2026.
  • ADC Therapeutics was a new Pallas Capital Advisors position in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #1021 holding.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.